Enveric Biosciences (ENVB) Competitors $0.62 +0.01 (+1.34%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENVB vs. LPTX, PHIO, MRKR, APLM, SNGX, LGVN, HOOK, MBIO, BCDA, and SNSEShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Leap Therapeutics (LPTX), Phio Pharmaceuticals (PHIO), Marker Therapeutics (MRKR), Apollomics (APLM), Soligenix (SNGX), Longeveron (LGVN), HOOKIPA Pharma (HOOK), Mustang Bio (MBIO), BioCardia (BCDA), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry. Enveric Biosciences vs. Its Competitors Leap Therapeutics Phio Pharmaceuticals Marker Therapeutics Apollomics Soligenix Longeveron HOOKIPA Pharma Mustang Bio BioCardia Sensei Biotherapeutics Leap Therapeutics (NASDAQ:LPTX) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Is LPTX or ENVB more profitable? Leap Therapeutics' return on equity of -237.65% beat Enveric Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -237.65% -155.38% Enveric Biosciences N/A -341.48%-240.71% Which has more risk and volatility, LPTX or ENVB? Leap Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Do insiders & institutionals believe in LPTX or ENVB? 30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 7.5% of Leap Therapeutics shares are held by insiders. Comparatively, 1.1% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor LPTX or ENVB? In the previous week, Leap Therapeutics had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 2 mentions for Leap Therapeutics and 1 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.91 beat Leap Therapeutics' score of 0.95 indicating that Enveric Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Leap Therapeutics Positive Enveric Biosciences Very Positive Which has preferable valuation and earnings, LPTX or ENVB? Leap Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$67.56M-$1.58-0.22Enveric BiosciencesN/AN/A-$9.57M-$38.38-0.02 Do analysts rate LPTX or ENVB? Leap Therapeutics presently has a consensus target price of $3.38, suggesting a potential upside of 864.29%. Enveric Biosciences has a consensus target price of $10.00, suggesting a potential upside of 1,550.17%. Given Enveric Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Enveric Biosciences is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEnveric Biosciences beats Leap Therapeutics on 7 of the 13 factors compared between the two stocks. Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.97M$3.11B$5.67B$10.37BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.0221.3775.8426.15Price / SalesN/A454.03561.11125.41Price / CashN/A45.2537.6061.28Price / Book0.269.7312.396.35Net Income-$9.57M-$52.93M$3.29B$271.10M7 Day Performance0.73%3.83%1.22%0.29%1 Month Performance-54.41%7.60%3.77%6.26%1 Year Performance-91.58%20.17%60.92%28.33% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences2.4043 of 5 stars$0.61-0.6%$10.00+1,550.2%-92.0%$1.97MN/A-0.0220LPTXLeap Therapeutics2.3552 of 5 stars$0.30-2.4%$3.38+1,017.5%-86.7%$12.39MN/A-0.1940News CoveragePHIOPhio Pharmaceuticals2.6799 of 5 stars$2.12-0.4%$14.00+560.1%-34.3%$12.20MN/A-0.6610MRKRMarker Therapeutics3.8675 of 5 stars$0.94-1.0%$13.17+1,306.7%-65.8%$12.11M$6.59M-0.6860Positive NewsAPLMApollomics0.5785 of 5 stars$11.56+24.5%N/A+35.5%$12.05M$1.49M0.0045Positive NewsSNGXSoligenix2.9204 of 5 stars$2.80+1.6%$6.00+114.7%-59.3%$12.00M$120K-0.7420News CoverageGap DownLGVNLongeveron2.8917 of 5 stars$0.75-0.5%$7.67+916.8%-59.3%$11.40M$2.39M-0.1220News CoverageHOOKHOOKIPA Pharma2.2289 of 5 stars$0.93+0.2%$4.50+383.9%-79.3%$11.34M$9.35M-0.16160MBIOMustang Bio0.946 of 5 stars$1.57-0.9%N/A-85.6%$11.29MN/A-0.02100Positive NewsBCDABioCardia3.468 of 5 stars$1.93-10.5%$25.00+1,198.7%-45.1%$11.17MN/A-1.0440Positive NewsAnalyst UpgradeInsider TradeAnalyst RevisionSNSESensei Biotherapeutics4.6463 of 5 stars$8.80-2.0%$55.00+525.0%-13.4%$11.03MN/A-0.4140Positive News Related Companies and Tools Related Companies LPTX Alternatives PHIO Alternatives MRKR Alternatives APLM Alternatives SNGX Alternatives LGVN Alternatives HOOK Alternatives MBIO Alternatives BCDA Alternatives SNSE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENVB) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
